Publication
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
| dc.contributor.author | Jr., Pedro N. Aguiar | |
| dc.contributor.author | Santoro, Ilka Lopes | |
| dc.contributor.author | Tadokoro, Hakaru | |
| dc.contributor.author | Lopes, Gilberto de Lima | |
| dc.contributor.author | Filardi, Bruno Andraus | |
| dc.contributor.author | Oliveira, Pedro | |
| dc.contributor.author | Mountzios, Giannis | |
| dc.contributor.author | de Mello, Ramon Andrade | |
| dc.date.accessioned | 2017-04-07T15:56:55Z | |
| dc.date.available | 2017-04-07T15:56:55Z | |
| dc.date.issued | 2016-04 | |
| dc.description.abstract | Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment. | |
| dc.identifier.doi | 10.2217/imt-2015-0002 | |
| dc.identifier.issn | 1750-743X | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/9557 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Future Medicine | |
| dc.relation.isbasedon | WOS:000372262400010 | |
| dc.title | The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis | |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 488 | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | 479 | |
| oaire.citation.title | Immunotherapy | |
| oaire.citation.volume | 8 | |
| rcaap.rights | restrictedAccess | |
| rcaap.type | article |
Files
Original bundle
1 - 1 of 1